använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.


Four new partners at Vator Securities

28 May 2021

Vator Securities was established ten years ago and continues to expand. Hereby the promotion of four employees to new partners is announced: Erik Sjöström, Erik Röjvall, Felicia Rittemar, and Anders Arviken. 

Through our new partners, Vator Securities further broadens and strengthens our knowledgebase. Acceding partners contribute with many years of professional experience and broad knowledge about, among other things, share analysis, project management, investment activities, and share management.

Read More

Vator Tech Days – Focus: Gaming

6 May 2021

Vator Securities welcomes you to Vator Tech Days – Focus: Gaming, a digital event where you get the opportunity to meet the most exciting fast-growing companies within Gaming and Esport.

The event takes place on May 26th at 09:00 to 16:45. Among the participating companies are  Modern Times Group, Enad Global 7, Media and Games Invest, Thunderful Group, 11 Bit Studios (PL), Epulze, Flexion, Adverty, Qiiwi, Safe Lane Gaming, and MAG Interactive.

Read More

Unlocking US reimbursement – the share price catalyst during 2021

16 April 2021

SciBase is delivering as we expected, and the share price is closing in on our target price. Recent news flow confirms the Nevisense EIS-technology’s potential for skin barrier assessment applications – an upside to both our and the market’s valuation of the company.

The apparent tangible driver of the share price for the coming 12 months, however, is unlocking US reimbursement (Medicare) where the US company DermTech offers a clear blueprint.

Read More

Vator Securities advises Respiratorius on 25 MSEK Directed Share Issue

13 April 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million.

Respiratorius AB is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.

Read More

Vator Securities advises Sprint Bioscience on 21 MSEK Directed Share Issue

8 April 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 21 million.

Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. With a fragment-based drug development method, the company develops drug projects in a time- and resource-efficient way that is outlicensed to global pharmaceutical companies during the preclinical phase.

Read More

Vator Securities advises Epulze on 57 MSEK Private Placement

6 April 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 57 million.

Epulze gives amateur players of computer games like Dota 2 and Counter-Strike: Global Offensive, the opportunity to participate in tournaments, leagues, and matches where real money is at stake. Among the new investors are well-known names such as Svea Ekonomi and Norwegian Carucel Finance, while Knutsson Holdings increases its ownership in the company.

Read More

Thou shall reimburse the one who finds the silent killer

29 March 2021

It may seem trivial to point out by now, but an accurate distinction between surveillance and screening is important in order to properly understand IMMray PanCan-d’s intended use, clinical utility offer and the parameters of importance to access the viability of the test to be included in guidelines and gaining broad reimbursement.

We still see confusion here.

Read More

Vator Securities advises CombiGene on 75 MSEK Rights Issue

8 March 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 75 million.

Having established the production platform for CG01, CombiGene’s intention in 2021 is to focus on the final parts of the preclinical program for CG01 with two major preclinical studies, a biodistribution study and a safety study, which will be conducted together with CombiGene’s CRO partners Northern Biomedical Research and Neurochase.

Read More